歌礼制药-B2025中期报告

2 4 5 29 35 36 37 38 40 42 43 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 24840 198D12 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 183171712-1716 1526 1672 www.ascletis.com 108 (i)ASC30Ib286.5%IIa125(ii)ASC30Ib36IIa(iii)ASC4740ASC4728(iv)ASC50-17(IL-17)I(v)(FASN)(ASC40)III(ASC40)III 1,827.92,117.2 130.332.5%88.0132.410.9%146.8 (i)(ii) 1.SagimetASC40 GLP-1RGLP-1THRββIL-17:-17FASN ASC30 ASC30(BMI)30-40kg/m2Ib(NCT06680440)ASC30IIa13 IbASC3046.5%ASC30Ib1(SAEs)(GI)(AE)12ASC30(weeklytitrations)(ALT)(AST)(TBL)ECGsQT(QTc) ASC30 FDA13IIa13IIa125 ASC30GLP-1RASC30(NCE) ASC3013IIa ASC30 ASC30Ib(NCT06679959)BMI30-40kg/m²ASC30ASC30IIa IbGLP-1RASC30100ASC30(ULAP)8ASC302(volume-matched) 36pHASC30100 GLP-1ASC30 ASC3012IIa ASC47 ASC47Ib ASC47LDL-CIb2640 ASC47900.2%291.0%431.7%50ASC47 ASC4790SAEAEAE1 (DIO)ASC471ASC47 3 mg/kg30nmol/kg30nmol/kg36.2%23.1%56.7% ASC47ASC47(68.8%)(66.0%) ASC47229ASC47–103NCT069729922828 ASC47THRβASC47 ASC47 IL-17ASC50 ASC50IL-17IIASC50(NCT07024602) ASC50IL-17IL-17ASC50(best-in-class) ASC50AI(AISBDD) 2025ASC50ISAD ASC40 (ASC40)III I I IF A S N(ASC40)18.6%FDAsarecycline9.4%doxycycline6.7%98%178%(ASC40)(18.6%)FDA(clascoterone)(11.6%)60% 50(ASC40)12(ASC40)treatment-emergent adverse eventsTEAETEAE10%TEAE5%(ASC40)6.3%2.9%(ASC40)5.9%3.8%(ASC40)AE(ASC40)34(ASC40) (ASC40)III 6.4130%40%2 (rGBM)ASC40 ASC40rGBM III MASH MASHASC40 ASC61 IPD-L1ASC61III(RP2D) ( i )A I( A I S B D D )( i i )(ULAP) 18A.08(3) 1.Tan J K, Bhate K. A global perspective on the epidemiology of acne [J]. Br J Dermatol 2015, 172 Suppl 1(3-12).DOI: 10.1111/bjd.13462. 2.Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the AcneTreatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. 17,000 11 1.ASC3013IIa2.ASC3012IIa3.ASC474.ASC50I5.(ULAP)6. 1,827.92,117.2 49.0103.6 49.0109.2%102.5(i)39.1SagimetSagimet10.7(ii)SagimetSagimet24.524.5(iii)12.234.221.1Sagimet 41.44.7%43.3 (i)(ii)(iii) 132.410.9%146.8 0.10.1 0.284.4%0.4 4.410.3%4.8 0.20.4 3090 9.163.9%14.9 1.224.8%0.9 53.579.3 7.420.7 2031 66.061.9 45.738.3 13.715.0 15.34.011.2 173.0142.5 904.6863.9 14.512.8 2.045.6%1.1 VikingTherapeutics,Inc.VikingASC41ASC43FITCUSDC ITCITCASC41ASC43F1930337567,0004,038,000 USDCVikingUSDC 0.40.6 (1)(2)(3)100% 12.914.612.814.5 7.5%6.5% 20820781.7% 82.176.8 20,013,1558,351,688 (b) 92,055,345 (i)(ii) (10) 38,561,400 12 (c) (d)13,700,0002,759,000 (%)0.00%(%)73%(%)3.93%2.804.01(%)0.00 33,741,225 4,820,1750.5% 0.005 (i)(ii) (10) 57,842,100 12 (e)23,195,0000.00 52,057,890 C1 C.2.1 3,440,00013,559,450 8,007,00036,889,790 5,784,210 (1)Vesync Co., Ltd2148 13.51B(1) XV352 1.L2.969,430,4953.JJW12Limited(BVI)514,393,6644.1,155,5001,000,0005.Lakemont Holding LLC82,827,414Lakemont Holding LLCLakemont Remainder Trust45.95%Northridge Trust53.52%Lakemont Remainder TrustNorthridgeTrust6.1,155,5001,000,0007.5,784,210JJW12LimitedJJW12Limited5,784,210 352 336 1.L2.969,430,4953.JJW11 Limited4.JJW12 Limited514,393,6645,784,210JJW12Limited5,784,2105.Lakemont Holding LLCLakemont Remainder Trust45.95%Northridge Trust53.52%6.C-Bridge Capital GP, Ltd.52,096,036C-Bridge Capital GP, Ltd.TF Capital II, Ltd.TF Capital,Ltd.38.34%45.00%Fu WeiTF Capital II, Ltd.47.83%7.Yang DanKang Hua Investment Company Limited52,096,036 336 224,137,0000.000114.003,137,918,0002,730,284,000 (i)(ii)(iii)(iv)(v) 554.817.7%793.7 2410 36553434 2410 34 108 1. 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands24840 2. 2.1 34 2.2 34 241035 2. 2.2 21 3. (a) (i) 15 1,054–27–1,081– NorthridgeHealth Group(HongKong) Co., LimitedNorthridge10%97.5% (b) 3. (c) (i)(ii) (i) (ii) 4. (i) (ii)Sagimet Biosciences Inc.Sagimet (iii)SagimetSagimetSagimetSagimetSagimetSagimet24,546,000SagimetSagimet 5. (a) (b) 6. 7. 87,951,000130,318,000962,523,0001,016,412,000 8. 1,072,0001,432,000 50,00050,000 9. 2,121,0003,950,000 10. 17 (i) (ii) 12. 13. 2,368,000 14. 370,338,000253,016,000 15. 16. (a) (b) 25713,810,00012,760,000 16. (c) 1,569,2853,849,0001,0003,848,000 (d) 44,896,79059,981,00032,00053,201,00053,233,000 (e) 4,820,1755,784,210 3.340 17. (a) (i) 13 ••• 17. (a) (ii) 18. 19. Viking Therapeutics, Inc.VikingASC41ASC43FITCUSDC ITCITC(AdministrativeLaw Judge)ASC41ASC43F1930337567,0004,038,000 USDCVikingUSDC 20. (a) (c) 20. (d) (i)29,389,00030,386,000F951F C1 FASN FDA IND LDL-C MASH C3 PBC